References
- YannuzziLASorensonJSpaideRFLipsonBIdiopathic polypoidal choroidal vasculopathy (IPCV)Retina1990101181693009
- YannuzziLACiardellaASpaideRFRabbMFreundKBOrlockDAThe expanding clinical spectrum of idiopathic polypoidal choroidal vasculopathyArch Ophthalmol199711544784859109756
- MarukoIIidaTSaitoMNagayamaDSaitoKClinical characteristics of exudative age-related macular degeneration in Japanese patientsAm J Ophthalmol20071441152217509509
- OishiAMiyamotoNMandaiMLAPTOP study: a 24-month trial of verteporfin versus ranibizumab for polypoidal choroidal vasculopathyOphthalmology201412151151115224484991
- KohALeeWKChenLJEVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathyRetina20123281453146422426346
- LaiTYLeeGKLukFOLamDSIntravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathyRetina20113181581158821610566
- LaiTYChanWMLiuDTLukFOLamDSIntravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathyBr J Ophthalmol200892566166618356265
- EconomidesANCarpenterLRRudgeJSCytokine traps: multi-component, high-affinity blockers of cytokine actionNat Med200391475212483208
- HolashJDavisSPapadopoulosNVEGF-Trap: a VEGF blocker with potent antitumor effectsProc Natl Acad Sci U S A20029917113931139812177445
- HeierJSBrownDMChongVfor VIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
- InoueMYamaneSTaokaRArakawaAKadonosonoKAflibercept for polypoidal choroidal vasculopathy: as needed versus fixed interval dosingRetina201536815271534
- HaraCSawaMSayanagiKNishidaKOne-year results of intravitreal aflibercept for polypoidal choroidal vasuculopathyRetina2016361374526383709
- ChoHJKimKMKimHSIntravitreal aflibercept and ranibizumab injections for polypoidal choroidal vasculopathyAm J Ophthalmol20161651626921806
- HosokawaMShiragaFYamashitaASix-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathyBr J Ophthalmol20159981087109125712826
- YamamotoAOkadaAAKanoMOne-year results of intravitreal aflibercept for polypoidal choroidal vasculopathyOphthalmology201512291866187226088619
- OishiATsujikawaAYamashiroKOne-year result of aflibercept treatment on age-related macular degeneration and predictive factors for visual outcomeAm J Ophthalmol20151595853860.e125634529
- KoizumiHKanoMYamamotoAAflibercept therapy for polypoidal choroidal vasculopathy: short-term results of a multicentre studyBr J Ophthalmol20159991284128825777816
- IjiriSSugiyamaKShort-term efficacy of intravitreal aflibercept for patients with treatment-naive polypoidal choroidal vasculopathyGraefes Arch Clin Exp Ophthalmol2015253335135725023147
- GregoriNZFeuerWRosenfeldPJNovel method for analyzing Snellen visual acuity measurementsRetina20103071046105020559157
- FingerRPWickremasingheSSBairdPNGuymerRHPredictors of anti-VEGF treatment response in neovascular age-related macular degenerationSurv Ophthalmol201459111824332379
- MatsumiyaWHondaSKusuharaSTsukaharaYNegiAEffectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-upBMC Ophthalmol2013131023557322
- KangHMKohHJLeeCSLeeSCCombined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcomeAm J Ophthalmol20141573598606.el24269378
- GomiFOshimaYMoriRInitial versus delayed photodynamic therapy in combination with ranibizumab for treatment of polypoidal choroidal vasculopathyRetina20153581569157625830698
- HiramiYTsujikawaAOtaniAHemorrhagic complications after photodynamic therapy for polypoidal choroidal vasculopathyRetina200727333534117460589